Loading...

Moleculin Biotech

DB:MOL
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MOL
DB
$102M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. The last earnings update was 60 days ago. More info.


Add to Portfolio Compare Print
  • Moleculin Biotech has significant price volatility in the past 3 months.
MOL Share Price and Events
7 Day Returns
23.7%
DB:MOL
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-34.7%
DB:MOL
-10.2%
DE Biotechs
-6%
DE Market
MOL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Moleculin Biotech (MOL) 23.7% -16% -21.5% -34.7% - -
DE Biotechs -2.4% 3.8% -8.6% -10.2% 51.2% 10.1%
DE Market 1.8% 6% 7.8% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • MOL underperformed the Biotechs industry which returned -10.2% over the past year.
  • MOL underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
MOL
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Moleculin Biotech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Moleculin Biotech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Moleculin Biotech.

DB:MOL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:MOL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:MOL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Moleculin Biotech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:MOL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -13.42 Analyst x1 -12.43
2020 -19.00 Analyst x1 -16.29
2021 -22.06 Analyst x1 -17.53
2022 -3.48 Analyst x1 -2.56
2023 13.05 Analyst x1 8.89
2024 15.44 Est @ 18.29% 9.74
2025 17.43 Est @ 12.87% 10.18
2026 19.01 Est @ 9.08% 10.29
2027 20.23 Est @ 6.42% 10.14
2028 21.15 Est @ 4.57% 9.82
Present value of next 10 years cash flows $10.26
DB:MOL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $21.15 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$273.63
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $273.63 ÷ (1 + 7.98%)10
$127.03
DB:MOL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $10.26 + $127.03
$137.28
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $137.28 / 34.38
$3.99
DB:MOL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:MOL represents 0.32419x of NasdaqCM:MBRX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.32419x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 3.99 x 0.32419
€1.29
Value per share (EUR) From above. €1.29
Current discount Discount to share price of €0.97
= -1 x (€0.97 - €1.29) / €1.29
25.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Moleculin Biotech is available for.
Intrinsic value
25%
Share price is €0.97 vs Future cash flow value of €1.29
Current Discount Checks
For Moleculin Biotech to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Moleculin Biotech's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Moleculin Biotech's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Moleculin Biotech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Moleculin Biotech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MOL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.46
NasdaqCM:MBRX Share Price ** NasdaqCM (2019-04-18) in USD $2.98
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Moleculin Biotech.

DB:MOL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:MBRX Share Price ÷ EPS (both in USD)

= 2.98 ÷ -0.46

-6.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Moleculin Biotech is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Moleculin Biotech is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Moleculin Biotech's expected growth come at a high price?
Raw Data
DB:MOL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
31.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Moleculin Biotech, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Moleculin Biotech's assets?
Raw Data
DB:MOL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.50
NasdaqCM:MBRX Share Price * NasdaqCM (2019-04-18) in USD $2.98
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:MOL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:MBRX Share Price ÷ Book Value per Share (both in USD)

= 2.98 ÷ 0.50

5.96x

* Primary Listing of Moleculin Biotech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Moleculin Biotech is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Moleculin Biotech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Moleculin Biotech has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Moleculin Biotech expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
31.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Moleculin Biotech expected to grow at an attractive rate?
  • Moleculin Biotech's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Moleculin Biotech's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Moleculin Biotech's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:MOL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MOL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 31.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MOL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MOL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 21 13 2
2022-12-31 11 -3 2
2021-12-31 0 -22 2
2020-12-31 0 -19 2
2019-12-31 0 -15 2
DB:MOL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -12 -12
2018-09-30 -11 -12
2018-06-30 -10 -13
2018-03-31 -9 -11
2017-12-31 -7 -10
2017-09-30 -6 -8
2017-06-30 -5 -7
2017-03-31 -5 -4
2016-12-31 -4 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Moleculin Biotech's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Moleculin Biotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MOL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Moleculin Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MOL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.25 0.25 0.25 1.00
2022-12-31 -0.07 -0.07 -0.07 1.00
2021-12-31 -0.47 -0.47 -0.47 1.00
2020-12-31 -0.48 -0.48 -0.48 1.00
2019-12-31 -0.43 -0.43 -0.43 1.00
DB:MOL Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.46
2018-09-30 -0.50
2018-06-30 -0.57
2018-03-31 -0.55
2017-12-31 -0.53
2017-09-30 -0.49
2017-06-30 -0.47
2017-03-31 -0.33
2016-12-31 -0.40

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Moleculin Biotech will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Moleculin Biotech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Moleculin Biotech has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Moleculin Biotech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Moleculin Biotech's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Moleculin Biotech does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Moleculin Biotech's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Moleculin Biotech's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Moleculin Biotech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Moleculin Biotech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MOL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -11.88 5.23 9.73
2018-09-30 -12.28 4.96 9.09
2018-06-30 -13.10 5.05 8.82
2018-03-31 -11.40 4.63 5.10
2017-12-31 -9.81 4.09 4.55
2017-09-30 -8.04 3.52 3.14
2017-06-30 -6.61 3.11 2.58
2017-03-31 -3.92 2.92 2.16
2016-12-31 -3.93 2.38 1.50
2015-12-31 -1.80 1.15 0.63

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Moleculin Biotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Moleculin Biotech has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Moleculin Biotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Moleculin Biotech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Moleculin Biotech has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Moleculin Biotech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Moleculin Biotech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Moleculin Biotech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Moleculin Biotech's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Moleculin Biotech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Moleculin Biotech has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Moleculin Biotech Company Filings, last reported 3 months ago.

DB:MOL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 14.27 0.00 7.13
2018-09-30 14.97 0.00 8.60
2018-06-30 16.75 0.00 11.72
2018-03-31 20.57 0.00 13.11
2017-12-31 17.12 0.00 7.71
2017-09-30 18.65 0.00 8.74
2017-06-30 19.27 0.00 9.27
2017-03-31 16.14 0.11 8.88
2016-12-31 14.96 0.30 5.01
2015-12-31 -0.74 0.45 0.03
  • Moleculin Biotech has no debt.
  • Moleculin Biotech currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Moleculin Biotech has less than a year of cash runway based on current free cash flow.
  • Moleculin Biotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 55.7% each year.
X
Financial health checks
We assess Moleculin Biotech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Moleculin Biotech has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Moleculin Biotech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Moleculin Biotech dividends.
If you bought €2,000 of Moleculin Biotech shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Moleculin Biotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Moleculin Biotech's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MOL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MOL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Moleculin Biotech has not reported any payouts.
  • Unable to verify if Moleculin Biotech's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Moleculin Biotech's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Moleculin Biotech has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Moleculin Biotech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Moleculin Biotech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Moleculin Biotech has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Moleculin Biotech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Wally Klemp
COMPENSATION $1,345,675
AGE 58
TENURE AS CEO 3.8 years
CEO Bio

Mr. Walter V. Klemp, also known as Wally, founded Moleculin Biotech, Inc. in July 2015 and has been its Chief Executive Officer since July 2015 and President since August 23, 2017. He is a Founder of Soliton, Inc. and serves as its Executive Chairman since July 2018. Mr. Klemp served as the President and Treasurer at Soliton, Inc. until July 2018. He served as Chief Executive Officer of Soliton, Inc. since November 2011 until July 2018, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. He co-founded Moleculin LLC and served as its Part-Time Chief Executive Officer. Mr. Klemp served as President and Chief Executive Officer of LumaTherm, Inc. (formerly Tyrell Inc.). He directed the Tyrell's development of its key product, Zeno, a medical device, intended for over-the-counter treatment of acne, that utilizes revolutionary new technology. Mr. Klemp served as President and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. Mr. Klemp founded Syntronyx Global Corporation. He served as the Chief Executive Officer of Syntronyx Global Corporation from 2001 to 2002. Prior to Syntronyx, he founded Drypers Corporation and served as its Chairman & Chief Executive Officer from 1987 to 2000. He started the Drypers Corporation with a college friend in his basement in the mid-1980s and eventually built it into a $400 million publicly traded company, with 2,400 employees and operations in seven countries. Prior to Drypers, Mr. Klemp was a CPA with Coopers & Lybrand (now PricewaterhouseCoopers). He has established a strong history of entrepreneurial achievement. Throughout his career, he has founded three companies and filed six U.S. patents. He has been Chairman of Moleculin Biotech, Inc. since July 2015. Mr. Klemp served as Chairman of Moleculin, L.L.C. He served as the chairman of Syntronyx Global Corporation from 2001 to 2002. He served as a Director of Drypers Corporation since February 1987. He serves as a Director of Soliton, Inc. He served as Member of Business Advisory Board at Moleculin Biotech, Inc. While a student, he was also recognized as Oregon's state champion orator. Mr. Klemp earned a B.A. from Lewis & Clark College, graduating with honors as the business school's “Outstanding Accounting Scholar.

CEO Compensation
  • Wally's compensation has increased whilst company is loss making.
  • Wally's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Moleculin Biotech management team in years:

2.7
Average Tenure
62
Average Age
  • The tenure for the Moleculin Biotech management team is about average.
Management Team

Wally Klemp

TITLE
Founder
COMPENSATION
$1M
AGE
58
TENURE
3.8 yrs

Jon Foster

TITLE
Executive VP & CFO
COMPENSATION
$846K
AGE
54
TENURE
2.7 yrs

Don Picker

TITLE
Chief Scientific Officer
COMPENSATION
$439K
AGE
72
TENURE
1.7 yrs

Waldemar Priebe

TITLE
Co-Founder and Chairman of Scientific Advisory Board

Rob Shepard

TITLE
Chief Medical Officer
AGE
66
TENURE
2.8 yrs

Sandra Silberman

TITLE
Chief Medical Officer of New Products
AGE
62
TENURE
1.4 yrs

Jacqueline Northcut

TITLE
Consultant
COMPENSATION
$69K
AGE
56
TENURE
1.8 yrs

Louis Ploth

TITLE
Independent Advisor
COMPENSATION
$118K
AGE
64
TENURE
2.7 yrs
Board of Directors Tenure

Average tenure and age of the Moleculin Biotech board of directors in years:

1.5
Average Tenure
66
Average Age
  • The average tenure for the Moleculin Biotech board of directors is less than 3 years, this suggests a new board.
Board of Directors

Waldemar Priebe

TITLE
Co-Founder and Chairman of Scientific Advisory Board

Robert George

TITLE
Independent Director
COMPENSATION
$107K
AGE
68
TENURE
2.8 yrs

Wally Klemp

TITLE
Founder
COMPENSATION
$1M
AGE
58
TENURE
3.8 yrs

Michael Cannon

TITLE
Independent Director
COMPENSATION
$101K
AGE
73
TENURE
2.8 yrs

John Climaco

TITLE
Lead Independent Director
COMPENSATION
$111K
AGE
49
TENURE
1.8 yrs

John Waymack

TITLE
Member of Scientific Advisory Board
AGE
66

Jorge Cortes

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

Elihu Estey

TITLE
Member of Scientific Advisory Board
TENURE
1.3 yrs

James Abbruzzese

TITLE
Member of Science Advisory Board
TENURE
0.3 yrs

Martin Tallman

TITLE
Member of Scientific Advisory Board
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Moleculin Biotech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Moleculin Biotech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) in the United States and Poland. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. Further, the company engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. It has an agreement with the University of Iowa Pharmaceuticals for the development of a formulation for WP1732; collaboration with Dermin Sp. zoo for the development of WP1220; and collaboration with M.D. Anderson Cancer Center for the development of WP1732 and WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Details
Name: Moleculin Biotech, Inc.
MOL
Exchange: DB
Founded: 2015
$91,008,888
34,384,030
Website: http://www.moleculin.com
Address: Moleculin Biotech, Inc.
5300 Memorial Drive,
Suite 950,
Houston,
Texas, 77007,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM MBRX Common Stock Nasdaq Capital Market US USD 02. Jun 2016
DB MOL Common Stock Deutsche Boerse AG DE EUR 02. Jun 2016
LSE 0K2H Common Stock London Stock Exchange GB USD 02. Jun 2016
Number of employees
Current staff
Staff numbers
11
Moleculin Biotech employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 22:28
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/02/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.